Neuvasq shared new preclinical data at Euretina

Neuvasq had the opportunity to share new preclinical data at Euretina, the most important European ophthalmology congress, which took place on September 4-7 in Paris.

In its poster, Neuvasq disclosed for the first time additional preclinical data confirming that its lead drug candidate, Ab NVQ401, was able to reverse disease phenotypes in different animal models of retinopathy. In particular, NVQ401 reduced neovascularization and avascularization in the Oxygen Induced Retinopathy (OIR) model, one of the most widely used models for drug candidates for Diabetic Macular Edema or wet Aged-related Macular Degeneration.